Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGM2 | P21980 | 11/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.44 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6034224 | 0.95 | TGM2 (0.59) | TGM2ALDH1A1HSD17B10MAPTGAA | |
| SCHEMBL6034953 | 0.94 | TGM2 (0.52) | TGM2ALDH1A1HSD17B10GAALMNA | |
| SCHEMBL6034875 | 0.91 | TGM2 (0.56) | TGM2ALDH1A1HSD17B10MAPTGAA | |
| SCHEMBL6033953 | 0.87 | TGM2 (0.62) | TGM2ALDH1A1HSD17B10MAPTGAA | |
| SCHEMBL6034265 | 0.87 | ALDH1A1 (0.52) | TGM2ALDH1A1HSD17B10MAPTGAA | |
| SCHEMBL6034917 | 0.83 | TGM2 (0.59) | TGM2ALDH1A1HSD17B10MAPTGAA | |
| SCHEMBL6034127 | 0.82 | TGM2 (0.58) | TGM2ALDH1A1HSD17B10MAPTGAA | |
| SCHEMBL6034191 | 0.82 | TGM2 (0.49) | TGM2ALDH1A1HSD17B10MAPTGAA | |
| SCHEMBL6034920 | 0.81 | TGM2 (0.60) | TGM2ALDH1A1HSD17B10MAPTGAA | |
| SCHEMBL6033368 | 0.81 | TGM2 (0.60) | TGM2ALDH1A1HSD17B10MAPTGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060183759-A1 | Tissue transglutaminase inhibitors | BRIGHAM AND WOMEN'S HOSPITAL, INC., THE | 2006-08-17 | — | — | US | disclosed |
| WO-2006060702-A1 | SUBSTITUED 3,4-DIHYDROTHIENO [2,3-D] PYRMIDINES AS TISSUE TRANSGLUTAMINASE INHIBITORS | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2006-06-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060183759-A1 | Tissue transglutaminase inhibitors | TGM2, HNMT, TPMT | TGM2 1/4885ALDH1A1 3116/4885HSD17B10 1221/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.